All In Biotech

Drug Trial Radar · NCT04904471

A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)

A Global Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cells), for the Prevention of COVID-19 in Adults Aged 18 Years and Older

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 39,663 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

39,663

Actual

Start

Jun 15, 2021

Primary completion

Jan 31, 2022

Study completion Nov 1, 2023

Sponsor

Lead sponsor
WestVac Biopharma Co., Ltd.Industry
Sponsor type
Industry
Collaborators
West China Hospital
First posted
May 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants aged 18 years and older who do not have a known history of SARS-CoV-2 infection but whose locations or circumstances put them at appreciable risk of acquiring COVID-19 or SARS-CoV-2 infection.

Conditions

  • COVID-19

Interventions

  • Recombinant COVID-19 vaccine (Sf9 cells)Biological

    This vaccine is made by using baculovirus as a vector and expressing SARS-CoV-2 S-RBD in Sf9 cells, which is purified by antigen isolation and added with aluminum hydroxide adjuvant for the prevention of COVID-19.

  • Placebo controlOther

    Except for the absence of study vaccine antigen, all other components (aluminum hydroxide, sodium chloride, sodium dihydrogen phosphate, disodium hydrogen phosphate) are consistent with the study vaccine and have been tested and qualified by National Institutes for Food and Drug Control.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Virologically confirmed (polymerase chain reaction(PCR) positive) symptomatic COVID-19 cases first occurring, regardless of severity.Time frame: 28 days after completion of 3 doses vaccination.
  2. The incidence of serious adverse events(SAEs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
  3. The incidence of adverse event of special interests(AESIs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
  4. The incidence of medically attended adverse events(MAAEs).Time frame: Day 0 to 6 months after completion of 3 doses vaccination.
  5. The incidence of solicited adverse events(AEs).Time frame: 0 to 7 days after each dose vaccination
  6. The incidence of unsolicited adverse events(AEs) .Time frame: 0 to 21 days after the first dose and the second dose vaccination, and 0 to 28 days after the third dose vaccination

Locations

24 sites in 5 countries. Site status is shown where the registry gives one.

  • Permata Hospital

    Bekasi, Indonesia

  • Brawijaya University Hospital

    Malang, Indonesia

  • Universitas Muhammadiyah Malang Hospital

    Malang, Indonesia

  • Airlangga University Hospital

    Surabaya, Indonesia

  • Husada Utama Hospital

    Surabaya, Indonesia

  • Puskesmas Ciketingudik

    Bekasi, Jiangsu, Indonesia

  • Moi Teaching and Referral Hospital,Eldoret (MTRH)

    Eldoret, Kenya

  • KAVI-Institute of Clinical Research, University of Nairobi

    Nairobi, Kenya

  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C.

    Durango, Mexico

  • Centro de Investigación Clínica y medicina traslacional (CIMeT)

    Guadalajara, Mexico

  • Hospital General Dr. Manuel Gea González

    Mexico City, Mexico

  • Invesclinic MX

    Mexico City, Mexico

  • Clínica de Enfermedades Crónicas y de Procedimientos Especiales

    Morelia, Mexico

  • SMIQ,S de R.L. de C.V.

    Querétaro, Mexico

  • FS Scientia Pharma SA de CV

    San Luis Potosí City, Mexico

  • Bharatpur Hospital

    Kathmandu, Nepal

  • Perpetual Succour Hospital - The Research Institute

    Cebu City, Philippines

  • St Luke Medical Centre - BGC

    City of Taguig, Philippines

  • De La Salle Medical and Health Sciences Institute

    Dasmariñas, Philippines

  • The Medical City - Iloilo

    Iloilo City, Philippines

  • West Visayas State University Medical Center

    Iloilo City, Philippines

  • Tropical Disease Foundation

    Makati City, Philippines

  • Makati Medical Center

    Makati City, Philippines

  • Quirino Memorial Medical Center

    Quezon City, Philippines

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.